Change in Kidney Function and 2-Year Mortality After Transcatheter Aortic Valve Replacement

Area of Science:

• Cardiology
• Nephrology
• Interventional Cardiology

Background:

• Chronic kidney disease (CKD) is common in patients undergoing transcatheter aortic valve replacement (TAVR).
• Limited data exist on TAVR's impact on kidney function and subsequent mortality.
• Understanding cardiorenal interactions post-TAVR is crucial.

Purpose of the Study:

• To evaluate changes in kidney function after TAVR.
• To assess the association between kidney function changes and midterm mortality following TAVR.

Main Methods:

• Retrospective cohort study of 894 patients undergoing TAVR.
• Kidney function assessed by estimated glomerular filtration rate (eGFR) at baseline and 1 month post-TAVR.
• Mortality assessed at 2-year follow-up.

Main Results:

• Over 80% of patients had stable or improved kidney function (eGFR change ≥10%) at 1 month post-TAVR.
• A 10% or greater eGFR deterioration was linked to a 2.16-fold increased risk of 2-year mortality.
• Improved kidney function post-TAVR was associated with similar 2-year mortality to those with baseline good kidney function.

Conclusions:

• Kidney outcomes after TAVR are generally favorable, with most patients maintaining or improving renal function.
• Post-TAVR kidney function improvement is linked to reduced mortality.
• Cardiorenal syndrome may be a significant factor, with TAVR offering potential for both cardiac and renal function improvement.